It would be great if we had a crystal ball to tell us which illnesses we’ll get and how to avoid them. Until we do, the next best thing is to know your risk factors for certain diseases, including ovarian cancer.
The FDA has approved rucaparib as a treatment for men who have advanced prostate cancer with mutated BRCA1/BRCA2 genes.
Prostate cancer is the number one cancer andthe second cause of cancer deaths among men in the USA. The mCRPC (metastatic, castrate-resistant prostate cancer) is incurable, but researchers are exploring possible treatment options.
Rucaparib falls under the PARP (Poly ADP-ribose polymerase) inhibitors class. The anti-cancer drugs target cancer cells with weakness, especially on how they repair their damaged DNA. The drugs have been used to treat ovarian cancer, and some inherited types of pancreatic and breast cancer.
mCRPC patients present poor outcomes when they use conventional treatment methods. Therefore, to treat patients with advanced prostate cancer, there needs to be personalized medicine. Twelve percent of patients with advanced prostate cancer have tumors with BRCA2/BRCA1 alteration. Therefore, the rucaparib FDA approval is exciting to patients, oncologists, and researchers.
The objective of the TRITON2 PHASE II study was to find out if rucaparib can effectively and safely treat men with mCRPC due to their genetic profile. The study participants included men who had completed chemotherapy and hormone therapy. The participants were given 600mg of rucaparib two times a day. The prostate-specific antigen levels in more than half the patients improved.
The researchers concluded that the anti-cancer drug had a similar safety profile with what they had experienced in other tumors. They, however, identified anemia as the most common side effect.
Research is underway to establish test combinations of PARP inhibitors with other experimental or conventional therapies to increase the number of mCRPC patients that benefit from the PARP inhibitor.
Patnaik, MD, Ph.D., and one of the research authors explains, “In a separate publication, we have demonstrated that additional non-BRCA1/2 mutations within the DNA repair pathway in mCRPC patients could confer sensitivity or resistance to PARP inhibitor rucaparib…. We still have a lot more to learn about which patients with additional genetically defined alterations in the DNA repair pathway will benefit most from this therapy.”
You Might Also Enjoy...
It would be great if we had a crystal ball to tell us which illnesses we’ll get and how to avoid them. Until we do, the next best thing is to know your risk factors for certain diseases, including ovarian cancer.
The calendar says summer’s coming to an end, but here in Texas, it’s summer all year long. That means you’re at high risk for skin cancer unless you take steps to prevent it. Here are five easy ones you can follow year round.
After your breast cancer diagnosis, your mind turns immediately to treatments. You want the most effective, least invasive option possible. Here’s why MammoSite® targeted radiation therapy may be the best answer.
You’d give up almost anything for a chance to beat your cancer. And many treatments will test your resolve to do just that. Hair loss is one of the sacrifices most-often associated with chemo and radiation. Here’s what you can expect.
Three oncology practices with a combined total of ten physicians have recently joined The Center for Cancer and Blood Disorders (The Center), the growing North Texas independent oncology practice, an affiliate of OneOncology, announced today.
Most people are familiar with radiation and chemotherapy as effective go-to treatments, but there are many more cancer-fighting weapons in our arsenal. Here’s how hormone therapy may be a key player in your cancer treatment plan.